This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:alternativeName |
|
| dbo:casNumber |
|
| dbo:class | |
| dbo:drugbank |
|
| dbo:fdaUniiCode |
|
| dbo:kegg |
|
| dbo:wikiPageExternalLink | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink |
|
| dbp:atcPrefix |
|
| dbp:atcSuffix |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:chemspiderid |
|
| dbp:class | |
| dbp:dailymedid |
|
| dbp:drugbank |
|
| dbp:h |
|
| dbp:kegg |
|
| dbp:legalUs |
|
| dbp:mabType |
|
| dbp:n |
|
| dbp:o |
|
| dbp:routesOfAdministration | |
| dbp:s |
|
| dbp:source |
|
| dbp:synonyms |
|
| dbp:target | |
| dbp:tradename |
|
| dbp:type |
|
| dbp:unii |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is dbp:medication of | |
| is foaf:primaryTopic of |